NCT02271412View on ClinicalTrials.gov

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Major Depressive Disorder, Recurrent, Unspecified
Interventions
DRUG

LY03005

LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.

DRUG

Placebo

Placebo

Trial Locations (1)

08053

PRA Health Sciences, Marlton

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT02271412 - Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005 | Biotech Hunter | Biotech Hunter